As a predictive biomarker for EGFR inhibitors in colorectal cancer (Gbenedio et al., 2019), RasGRP1 has been linked to several cancer-related processes, such as hepatocarcinoma carcinogenesis (Zhang et al., 2024) and displaying an association with improved overall survival in breast cancer (Wang B. et al., 2018). Here, EGFR is linked to breast carcinoma.